News

Incruse is a once-daily long-acting muscarinic antagonist (LAMA), a type of bronchodilator also known as an anticholinergic. Currently licensed across all EU member states, Incruse is a 55mcg

A full analysis of the trial’s results is scheduled to be completed in the third quarter of 2014, but preliminary data suggests that GM604 shows significant promise for

Nexavar is co-developed by Onyx Pharmaceuticals, an Amgen subsidiary, and Bayer HealthCare Pharmaceuticals, except in Japan where Bayer manages all development. In November 2013, the European Commission (EC)

Trametinib as a single agent has not showed clinical activity in patients who have progressed on a prior BRAF inhibitor therapy. According to the company, before taking trametinib,

Initial focus in the deal for SNBL is to promote Crown Bioscience services to its Japanese clients, in doing so extending SNBL’s service offering. Under the deal, SNBL

The new drug uses Novozymes’ Veltis technology to achieve an extended half-life that means patients are only required to inject their medication once a week. The approval follows

The trail met its primary objective and the once-daily Onbrez Breezhaler (indacaterol) 150mcg showed non-inferiority in lung function at week 12 to twice-daily Seretide (salmeterol/fluticasone propionate (SFC)) 50/500mcg

The announcement by Bill Gates, co-chair of the Bill & Melinda Gates Foundation, accompanied a commitment of significant funding by the Gates Foundation to determine the safety and

FDA issued a decision holding that eligibility for 180 days of exclusivity is only available to an applicant who first filed a PIV certification to an original patent